AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BioGaia

Regulatory Filings Jun 11, 2009

3013_rns_2009-06-11_6d5ac39e-ca25-4eec-ba2a-47374234fbea.pdf

Regulatory Filings

Open in Viewer

Opens in native device viewer

Press Release 11 June 2009

BioGaia signs distribution agreement in Germany.

BioGaia has signed an exclusive distribution agreement for BioGaia's Probiotic Drops with the German pharmaceutical company InfectoPharm. The product will be sold under the BioGaia brand.

"InfectoPharm has a strong position and recognition among pediatricians making them an ideal partner for our top selling BioGaia Drops, and we are now confident and eager to take on the challenging German market ", says Peter Rothschild, President, BioGaia AB.

"We have closely followed the success of the BioGaia Drops in many other European markets and see a big need for this product also for the children in Germany" says Dr. Manfred Zöller, President at InfectoPharm.

InfectoPharm is a German pharmaceutical company with a strong pediatric portfolio. The company with headquarters in Heppenheim, Germany, covers the whole area of infectious diseases, gastroenterology, dermatology and pneumology. They represent the market leaders in their particular market niches.

To learn more about INFECTOPHARM or its products please visit www.infectopharm.com.

Latest press releases from BioGaia: 2009-04-23 Annual General Meeting of BioGaia 2009-04-22 Interim report 1 January – 31 March 2009 2009-03-18 Notice to attend the Annual General Meeting of BioGaia AB

For additional information contact:

Peter Rothschild, Managing Director, telephone: +46 8 -555 293 00 Jan Annwall, Deputy Managing Director, telephone: +46 8-555 293 00

BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.